ArcherDX, Inc., a Boulder, CO-based developer of NGS-based gene fusion detection assays, closed a $35m Series A financing.
The round was was co-led by Boulder Ventures, Ltd. and PBM Capital Group, LLC. Longwood Fund and Peierls Foundation also participated in the Series A financing as new investors. Kyle Lefkoff of Boulder Ventures has joined the ArcherDX Board of Directors.
The company will use the funding to support the rapid commercial growth of its targeted sequencing assays, including expanding its domestic salesforce, increasing its international commercial operations, scaling its oncology-focused CDx co-development program and continuing to invest in its in vitro diagnostic (IVD) pipeline.
Led by Dr. Jason Myers, CEO and Co-founder, ArcherDX offers a bioinformatics platform for targeted sequencing applications featuring proprietary Anchored Multiplexed PCR (AMP™) chemistry in a lyophilized format.